ArticleAntimicrobial resistance and infection control2018
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Article in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models.Clinical pharmacokinetics · 2020Pooled it
- Pooled it
- Tandem amplification of theMicrobiology spectrum · 2026Article
- Metabolic activation of pyruvate cycle by protocatechualdehyde triggers oxidative killing of ampicillin-resistantMicrobiology spectrum · 2026Article
- Synergistic effects of ceftriaxone combined with BLI-489 against NDM-producingMicrobiology spectrum · 2026Article
- Combination Therapy with Ceftazidime-Avibactam, Aztreonam, and Topical Polymyxin B for NDM-ProducingInfection and drug resistance · 2026Article
- Interpretable machine learning of clinical MALDI-TOF spectra discriminates carbapenem-resistantJournal of mass spectrometry and advances in the clinical lab · 2025Article
- Exposure to ceftazidime-avibactam induced antimicrobial resistance and enhanced virulence in aiScience · 2025Article
- Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales.Antibiotics (Basel, Switzerland) · 2025Article
- Aztreonam Acts as a Synergist for Ceftazidime/Avibactam Against Carbapenem-ResistantInfection and drug resistance · 2025Article
- Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistantAntimicrobial agents and chemotherapy · 2024Article
- Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2024Review
- Development and evaluation of rapid and simple detection ofFrontiers in microbiology · 2024Article
- PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistantFrontiers in microbiology · 2024Article
- Antimicrobial activity of phenyllactic acid against Klebsiella pneumoniae and its effect on cell wall membrane and genomic DNA.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11Microbiology spectrum · 2023Article
- Combination of AS101 and Mefloquine Inhibits Carbapenem-ResistantInfection and drug resistance · 2023Article
- In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales ProducingInfection and drug resistance · 2023Article
- Identification of KPC-112 from an ST15 Klebsiella pneumoniae Strain Conferring Resistance to Ceftazidime-Avibactam.mSphere · 2022Article
- Panorama of Bacterial Infections Caused by Epidemic Resistant Strains.Current microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, the incidence of carbapenem-resistant Methods: The microdilution broth method was performed to analyze the minimal inhibitory concentration (MIC). The time-kill curve assay of ceftazidime-avibactam at various concentrations was conducted in 16 strains of KPC-2 and 1 strain of OXA-232 carbapenemase-producing Results: The time-kill assays revealed that ceftazidime-avibactam at various concentrations of 2MIC, 4MIC and 8MIC showed significant bactericidal efficiency to the resistant bacteria strains. However, in 28 strains of NDM and 2 strains of NDM coupled with KPC carbapenemase- producing Conclusion: This study indicated ceftazidime-avibactam therapy occupied significant bactericidal effects against KPC-2 and OXA-232 carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.